The most logical approach would be to lump all of these lesions under the rubric of “TRK-fusion associated tumor of intermediate malignant potential” to include both LPF-like neural tumors and IFs as well as NTRK1 fusion sarcomas. The gene discussed is NTRK1; the disease is sarcoma.